EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience

Marisa Dorling, Masih Sarafan, Béatrice Voizard, Yousif Al Ammar, Juan Carlos Hernaiz-Leonardo iD, Kieran Chalmers, Patrick MacInnis, James Nugent, Arif Janjua, Amin Javer iD, Doron Sommer, John Lee und 2 weitere

International Forum of Allergy & Rhinology · 2025-02 · 15 (2) · 166-173

DOI: 10.1002/alr.23466 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 18.10.2024. Verfasst von Marisa Dorling und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Otolaryngology-Head & Neck Surgery, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Rhinitis, Biological Products. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 biologics have been used increasingly for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). However, patterns of biologic switching are understudied, and established guidelines for sequential or simultaneous use do not yet exist.

Methods

This is a Canadian multicenter retrospective study of real‐world patient data. Patients were included if they had recurrent CRSwNP despite maximal medical and surgical management, and received at least one dose of a type 2 biologic. Patients who remained on their initial biologic comprised the continuous group. Patients with sequential or simultaneous use of more than one biologic comprised the switched group. We compared the characteristics of patients who continued and switched biologics.

Results

Note that 225 consecutive patients were included. Thirty‐six (16%) switched biologics at least once, and six (3%) switched twice. The most common switch was from mepolizumab to dupilumab, with poor control of CRSwNP symptoms being the leading cause for this switch. Lack of efficacy was the main reason for switching off mepolizumab and omalizumab, while adverse events were the leading cause for switching off dupilumab. Additionally, mepolizumab patients were more likely to switch biologics late in their treatment, while dupilumab patients rarely switched after 12 months of therapy ( p ‐value < 0.001).

Conclusions

Switching biologics for CRSwNP is frequent in Canadian rhinology practices, with 16% of patients switching at least once. The most common switch is from mepolizumab to dupilumab with inadequate CRSwNP control driving this switch. This study may help guide sequential or simultaneous use of biologics in CRSwNP patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisNasal PolypsRhinitisBiological ProductsDrug SubstitutionHumansCanadaChronic DiseaseFemaleMaleMiddle AgedRetrospective StudiesAdultAntibodies, Monoclonal, HumanizedAgedRhinosinusitis

Stichwörter der Autor:innen

asthmabiologicschronic rhinosinusitischronic rhinosinusitis with nasal polyposislower airway diseasetype 2 inflammationupper airway disease

Substanzen

Biological ProductsAntibodies, Monoclonal, Humanizeddupilumabmepolizumab

Autor:innen und Institutionen

  • Division of Otolaryngology-Head & Neck Surgery, University of British Columbia, Vancouver, Canada.
  • Division of Otolaryngology-Head & Neck Surgery, McMaster University, Hamilton, Canada.
  • Department of Otolaryngology-Head & Neck Surgery, University of Toronto, Toronto, Canada.

ORCID-Profile: Juan Carlos Hernaiz-Leonardo, Amin Javer

Zitieren

APA

Dorling, M., Sarafan, M., Voizard, B., Ammar, Y. A., Hernaiz-Leonardo, J. C., Chalmers, K., MacInnis, P., Nugent, J., Janjua, A., Javer, A., Sommer, D., Lee, J., Chan, Y., & Thamboo, A. (2025). Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience. International Forum of Allergy & Rhinology, 15(2), 166-173. https://doi.org/10.1002/alr.23466

Vancouver

Dorling M, Sarafan M, Voizard B, Ammar YA, Hernaiz-Leonardo JC, Chalmers K, et al. Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience. International Forum of Allergy & Rhinology. 2025;15(2):166-173. doi:10.1002/alr.23466

BibTeX
@article{Dorling2025,
  author = {Dorling, Marisa and Sarafan, Masih and Voizard, Béatrice and Ammar, Yousif Al and Hernaiz-Leonardo, Juan Carlos and Chalmers, Kieran and MacInnis, Patrick and Nugent, James and Janjua, Arif and Javer, Amin and Sommer, Doron and Lee, John and Chan, Yvonne and Thamboo, Andrew},
  title = {Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  volume = {15},
  number = {2},
  pages = {166--173},
  doi = {10.1002/alr.23466}
}
Kostenlos starten →